Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

205,354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy.
Wang X, Li W, Yin Y, Tong Z, Zhang Q, Zheng H, Shao Z, Li H, Yang J, Feng J, Wu F, Lamour F, Restuccia E, Jiang Z. Wang X, et al. Transl Breast Cancer Res. 2023 Jan 31;4:3. doi: 10.21037/tbcr-23-2. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751488 Free PMC article.
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.
Xu B, Li W, Zhang Q, Li Q, Wang X, Li H, Sun T, Yin Y, Zheng H, Feng J, Zhu H, Siddiqui A, Macharia H, Knott A. Xu B, et al. Among authors: wang x. Breast Cancer Res Treat. 2023 Feb;197(3):503-513. doi: 10.1007/s10549-022-06775-1. Epub 2022 Dec 4. Breast Cancer Res Treat. 2023. PMID: 36463547 Free PMC article. Clinical Trial.
Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial.
Li H, Huang Y, Chen Z, Zeng A, Zhang H, Yu Y, Wei S, Li Q, Wang X, Wang X, Wang X, Yang R, Dai X, Bi M, Sun T, Zhang Q, Han C, Li Y, Kang X, Liu Y, Zhang L. Li H, et al. Among authors: wang x. BioDrugs. 2023 Mar;37(2):259-269. doi: 10.1007/s40259-023-00579-5. Epub 2023 Feb 21. BioDrugs. 2023. PMID: 36802320 Free PMC article. Clinical Trial.
Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study.
Wang T, Zhang P, Di L, Wang X, Yang J, Tong Z, Liu J, Feng J, Liu D, Yu Q, Liu Y, Yu H, Jiang Z. Wang T, et al. Among authors: wang x. Transl Breast Cancer Res. 2022 Apr 30;3:15. doi: 10.21037/tbcr-21-42. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751509 Free PMC article.
Efficacy and safety of margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study.
Zhang Q, Ouyang Q, Li W, Chiu J, Yan M, Lu YS, Sun S, Li H, Du Y, Wang X, Sun T, Yin Y, Wang H, Ye F, Shen K, Wang J, Pan Y, Wang S, Yang J, Wu X, Dai MS, Cheng J, Teng Y, Su F, Wu X, He J, Fu P, Yang L, Xin Y, Wang X, Jiang Z. Zhang Q, et al. Among authors: wang x, wang h, wang j, wang s. Transl Breast Cancer Res. 2022 Oct 31;3:31. doi: 10.21037/tbcr-22-35. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751523 Free PMC article.
Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition).
Li J, Wang X, Wang S, Wang S, Wang T, Liu Y, Geng C, Jin F, Yin Y, Zhang Q, Song E, Wu J, Jiang Z; Chinese Society of Clinical Oncology Breast cancer committee; Chinese Anti-Cancer Association; Committee of Breast Cancer Society. Li J, et al. Among authors: wang x, wang t, wang s. Transl Breast Cancer Res. 2022 Oct 31;3:30. doi: 10.21037/tbcr-22-48. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751529 Free PMC article. Review.
Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022.
Jiang Z, Li J, Chen J, Liu Y, Wang K, Nie J, Wang X, Hao C, Yin Y, Wang S, Yan M, Wang T, Yan Y, Chen X, Song E; CSCO BC guideline working group. Jiang Z, et al. Among authors: wang x, wang k, wang t, wang s. Transl Breast Cancer Res. 2022 Apr 30;3:13. doi: 10.21037/tbcr-22-21. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751537 Free PMC article. Review.
BOLERO-5: a phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER + /HER2- advanced breast cancer.
Shao ZM, Cai L, Wang S, Hu X, Shen K, Wang H, Li H, Feng J, Liu Q, Cheng J, Wu X, Wang X, Li H, Luo T, Liu J, Amin K, Slimane K, Qiao Y, Liu Y, Tong Z. Shao ZM, et al. Among authors: wang h, wang x, wang s. Discov Oncol. 2024 Jun 21;15(1):237. doi: 10.1007/s12672-024-01027-8. Discov Oncol. 2024. PMID: 38904918 Free PMC article.
205,354 results
You have reached the last available page of results. Please see the User Guide for more information.